Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

4.235 -0.175 (-3.97%)
Streaming Delayed Price Updated: 2:23 PM EDT, Apr 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other Highlights
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Why Xeris Pharmaceuticals Is Soaring 7% Higher Today
The biopharma is starting to put together a string of good news advances. 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 14.64% to $2.08 during Monday's regular session. The current volume of 7.2 million shares is 300.39% of Jaguar... 
Via Benzinga
Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday
The 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021
Upgrades For Preferred Bank (NASDAQ: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 28.64% to $2.47 during Monday's pre-market session. The company's market cap stands at $38.1 million.... 
Via Benzinga
Xeris Pharmaceuticals Enters Collaboration Agreement With Merck
From Xeris Biopharma Holdings, Inc.
Via Business Wire
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
45 Biggest Movers From Yesterday
Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial... 
Via Benzinga
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
From Xeris Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Xeris Pharmaceuticals (NASDAQ:XERS 
Via Benzinga
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma
From Xeris Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Cardiff Oncology (NASDAQ: 
Via Benzinga
Xeris Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Xeris Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Exposures COVID-19
Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge Biopharma
From Xeris Pharmaceuticals, Inc.
Via Business Wire
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) rose 40.1% to $21.43 in pre-market trading after gaining over 11% on Tuesday. Regencell Bioscience recently reported... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Triple-S Management (NYSE:GTS) stock moved upwards by 44.27% to $34.9 during Tuesday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share,... 
Via Benzinga
Why Xeris Pharmaceuticals Shares Traded Higher Today
Xeris Pharmaceuticals Inc (NASDAQ: XERS) is trading significantly higher Monday after the company announced U.S. Food and Drug Administration approval of its... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock rose 45.44% to $5.58 during Monday's regular session. As of 12:30 EST, Vivos Therapeutics's stock is trading at a... 
Via Benzinga
35 Stocks Moving In Monday's Mid-Day Session
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares climbed 187.8% to $17.53 after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value... 
Via Benzinga
Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Strengthens Its Patent Estate
From Xeris Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.